Medicare Enrolled
Dr. Stanlee Lu, M.D.
Medical Oncology · Fife, WA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lu from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lu?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lu
Dr. Stanlee Lu is a medical oncology specialist in Fife, WA, with 16 years of NPI registration. Based on federal Medicare data, Dr. Lu performed 22,815 Medicare services across 356 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lu received a total of $5,986 from 63 pharmaceutical and/or device companies across 326 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lu is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 11% volume in WA
$5,986 industry payments
Medicare Practice Summary
Medicare Utilization ↗22,815
Medicare services
Top 11% in WA for medical oncology
356
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,426 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
21,000 | $1 | $6 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
740 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
240 | $8 | $65 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
211 | $95 | $681 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
194 | $11 | $82 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
149 | $105 | $764 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
111 | $23 | $166 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
65 | $48 | $377 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
64 | $59 | $483 |
| New patient office visit, complex (60-74 min) | 26 | $148 | $1,167 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
15 | $123 | $883 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
93.5% high complexity
4.1% medium
2.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,986
Total received (2018-2024)
Avg $855/year across 7 years
Top 40% in WA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
63
Companies
326
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,731 (95.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$255 (4.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,529
2023
$1,399
2022
$765
2021
$512
2020
$74
2019
$748
2018
$959
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$209
Novartis Pharmaceuticals Corporation
$155
PFIZER INC.
$137
Celgene Corporation
$135
GlaxoSmithKline, LLC.
$120
Genentech USA, Inc.
$68
AstraZeneca Pharmaceuticals LP
$66
Regeneron Healthcare Solutions, Inc.
$59
Gilead Sciences, Inc.
$55
Stemline Therapeutics Inc.
$49
Janssen Biotech, Inc.
$41
EMD Serono, Inc.
$37
Mirati Therapeutics, Inc.
$34
ARRAY BIOPHARMA INC
$33
Takeda Pharmaceuticals U.S.A., Inc.
$31
Ipsen Biopharmaceuticals, Inc
$30
Astellas Pharma US Inc
$30
ACCORD HEALTHCARE, INC.
$24
Bayer Healthcare Pharmaceuticals Inc.
$22
E.R. Squibb & Sons, L.L.C.
$22
Coherus Biosciences Inc.
$22
Alnylam Pharmaceuticals Inc.
$20
MorphoSys, US Inc.
$20
ADC Therapeutics America, Inc.
$18
Aveo Pharmaceuticals, Inc.
$18
Adaptive Biotechnologies Corporation
$17
Fresenius Kabi USA, LLC
$15
Sumitomo Pharma America, Inc.
$15
Acrotech Biopharma Inc.
$14
Echosens North America, Inc.
$13
Top 3 companies account for 32.7% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$585
Novartis Pharmaceuticals Corporation
$454
Janssen Biotech, Inc.
$429
Pharmacyclics LLC, An AbbVie Company
$400
ABBVIE INC.
$351
Celgene Corporation
$266
Genentech USA, Inc.
$247
Astellas Pharma US Inc
$232
PFIZER INC.
$209
Boehringer Ingelheim Pharmaceuticals, Inc.
$201
GENZYME CORPORATION
$186
GlaxoSmithKline, LLC.
$184
AstraZeneca Pharmaceuticals LP
$178
Gilead Sciences, Inc.
$104
EMD Serono, Inc.
$100
Bayer Healthcare Pharmaceuticals Inc.
$90
Bayer HealthCare Pharmaceuticals Inc.
$83
ARRAY BIOPHARMA INC
$80
Janssen Products, LP
$80
Merck Sharp & Dohme Corporation
$79
Seagen Inc.
$78
SOBI, INC
$74
Daiichi Sankyo Inc.
$72
Incyte Corporation
$62
MorphoSys, US Inc.
$60
Regeneron Healthcare Solutions, Inc.
$59
Amgen Inc.
$57
Octapharma USA, Inc.
$56
Pharmacyclics LLC, an AbbVie Company
$55
Mirati Therapeutics, Inc.
$55
Stemline Therapeutics Inc.
$49
Taiho Oncology, Inc.
$49
Coherus Biosciences Inc.
$48
Takeda Pharmaceuticals U.S.A., Inc.
$46
Ipsen Biopharmaceuticals, Inc
$45
Eisai Inc.
$38
Fresenius Kabi USA, LLC
$37
Acrotech Biopharma Inc.
$35
Clovis Oncology, Inc.
$27
TerSera Therapeutics LLC
$25
Exelixis Inc.
$24
ACCORD HEALTHCARE, INC.
$24
CTI BioPharma Corp.
$24
GE HEALTHCARE
$24
Merck Sharp & Dohme LLC
$22
Pharmacosmos Therapeutics Inc.
$21
Epizyme, Inc.
$21
Alnylam Pharmaceuticals Inc.
$20
Blueprint Medicines Corporation
$20
Sobi, Inc
$19
MEDIVATION FIELD SOLUTIONS LLC
$19
Epizyme, Inc.,
$19
Dendreon Pharmaceuticals LLC
$18
ADC Therapeutics America, Inc.
$18
Aveo Pharmaceuticals, Inc.
$18
Adaptive Biotechnologies Corporation
$17
AVEO Pharmaceuticals, Inc.
$15
EISAI INC.
$15
Sumitomo Pharma America, Inc.
$15
Echosens North America, Inc.
$13
Verastem, Inc.
$12
Dova Pharmaceuticals
$11
Fortovia Therapeutics, Inc.
$8
Top 3 companies account for 24.5% of all-time payments
Associated products mentioned in payments ›
6 · ADCETRIS · ALUNBRIG · AUGTYRO · AYVAKIT · Abraxane · Alecensa · Avastin · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · Bavencio · CALQUENCE · CAMCEVI · COSELA · CRESEMBA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · EMPLICITI · ENJAYMO · EPKINLY · ERLEADA · Erleada · FOTIVDA · Fabhalta · FibroScan · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Itovebi · JAKAFI · JEVTANA · Jivi · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LONSURF · LORBRENA · LUMOXITI · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · Nplate · Nubeqa · OCTAGAM · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONPATTRO · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Orserdu · PADCEV · PEMAZYRE · PREVYMIS · PROMACTA · PROVENGE · Perjeta · Phesgo · Pomalyst · REBLOZYL · Rubraca · SARCLISA · SCEMBLIX · SPRYCEL · SUTENT · Stimufend · Stivarga · TASIGNA · TAZVERIK · TECENTRIQ · TEPMETKO · TIVDAK · TUKYSA · Tazverik · Trodelvy · Udenyca · VENCLEXTA · Vonjo · XGEVA · XOSPATA · XTANDI · Xermelo · Xofigo · Xospata · ZEJULA · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
13
Per 100K population
1.4
County median income
$96,632
Nearest hospital
MULTICARE GOOD SAMARITAN HOSPITAL
4.7 mi
4.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lu is a mixed practice specialist, with above-average Medicare volume (top 11% in WA), with low-engagement industry engagement, with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lu experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Lu performed 21,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lu receive payments from pharmaceutical companies?
Yes. Dr. Lu received a total of $5,986 from 63 companies across 326 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lu's costs compare to other medical oncologists in Fife?
Dr. Lu's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lu) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Fife
Browse medical oncologists in Fife ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in WA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in WA
Which WA medical oncologists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology